BR112012019511A2 - compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. - Google Patents
compostos de pirrolo [2,3-d] pirimidina como inibidores de jak.Info
- Publication number
- BR112012019511A2 BR112012019511A2 BR112012019511A BR112012019511A BR112012019511A2 BR 112012019511 A2 BR112012019511 A2 BR 112012019511A2 BR 112012019511 A BR112012019511 A BR 112012019511A BR 112012019511 A BR112012019511 A BR 112012019511A BR 112012019511 A2 BR112012019511 A2 BR 112012019511A2
- Authority
- BR
- Brazil
- Prior art keywords
- jak
- inhibitors
- pyrrolo
- pyrimidine compounds
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- CDTHSJBAARJOGY-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine;urea Chemical class NC(N)=O.N1=CNC2=NC=CC2=C1 CDTHSJBAARJOGY-UHFFFAOYSA-N 0.000 abstract 1
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 pyrrolo {2,3} pyrimidine compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30191510P | 2010-02-05 | 2010-02-05 | |
| PCT/US2011/022216 WO2011097087A1 (en) | 2010-02-05 | 2011-01-24 | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012019511A2 true BR112012019511A2 (pt) | 2016-08-23 |
Family
ID=43629121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012019511A BR112012019511A2 (pt) | 2010-02-05 | 2011-01-24 | compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120309776A1 (https=) |
| EP (1) | EP2531508A1 (https=) |
| JP (1) | JP2013518882A (https=) |
| CN (1) | CN102822177A (https=) |
| AU (1) | AU2011213198B2 (https=) |
| BR (1) | BR112012019511A2 (https=) |
| CA (1) | CA2788071A1 (https=) |
| MX (1) | MX2012009074A (https=) |
| WO (1) | WO2011097087A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| EP2895172B1 (en) | 2012-09-12 | 2019-02-06 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
| CN113384546A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| EP2951590A1 (en) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| EP3006445B1 (en) * | 2013-06-07 | 2017-11-15 | Jiangsu Hengrui Medicine Co. Ltd. | Bisulfate of janus kinase (jak) inhibitor and preparation method therefor |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| CN105732637B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| ES2784523T3 (es) | 2015-11-24 | 2020-09-28 | Theravance Biopharma R&D Ip Llc | Profármacos de un compuesto inhibidor de JAK para el tratamiento de enfermedades inflamatorias gastrointestinales |
| WO2017143014A1 (en) | 2016-02-16 | 2017-08-24 | Brian Kim | Jak inhibitors and uses thereof |
| US10472366B2 (en) | 2017-03-08 | 2019-11-12 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of tofacitinib |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| WO2018189335A1 (en) | 2017-04-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| BR112019024509A2 (pt) | 2017-05-23 | 2020-06-23 | Theravance Biopharma R&D Ip, Llc | Glicuronídeo de pró-fármacos dos inibidores da janus quinase |
| WO2018217699A1 (en) | 2017-05-23 | 2018-11-29 | Theravance Biopharma R&D Ip, Llc | Thiocarbamate prodrugs of tofacitinib |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE247469T1 (de) * | 1995-06-07 | 2003-09-15 | Pfizer | Heterocyclische kondensierte pyrimidin-derivate |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| BR9911365A (pt) | 1998-06-19 | 2001-03-13 | Pfizer Prod Inc | Compostos pirrolo[2,3-d]pirimidina |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| IL152771A0 (en) * | 2000-06-26 | 2003-06-24 | Pfizer Prod Inc | PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| EP1299352B1 (en) * | 2000-06-30 | 2005-12-28 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| KR100678800B1 (ko) | 2002-11-21 | 2007-02-05 | 화이자 프로덕츠 인코포레이티드 | 3-아미노-피페리딘 유도체 및 그의 제조 방법 |
| US7732237B2 (en) | 2005-06-27 | 2010-06-08 | The Regents Of The University Of California | Quantum dot based optoelectronic device and method of making same |
| BRPI0613876A2 (pt) * | 2005-07-29 | 2011-02-15 | Pfizer Prod Inc | derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese |
| WO2008029237A2 (en) * | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
-
2011
- 2011-01-24 JP JP2012551997A patent/JP2013518882A/ja not_active Withdrawn
- 2011-01-24 EP EP11703762A patent/EP2531508A1/en not_active Withdrawn
- 2011-01-24 AU AU2011213198A patent/AU2011213198B2/en not_active Expired - Fee Related
- 2011-01-24 MX MX2012009074A patent/MX2012009074A/es unknown
- 2011-01-24 CN CN2011800171067A patent/CN102822177A/zh active Pending
- 2011-01-24 US US13/576,685 patent/US20120309776A1/en not_active Abandoned
- 2011-01-24 BR BR112012019511A patent/BR112012019511A2/pt not_active IP Right Cessation
- 2011-01-24 CA CA2788071A patent/CA2788071A1/en not_active Abandoned
- 2011-01-24 WO PCT/US2011/022216 patent/WO2011097087A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2788071A1 (en) | 2011-08-11 |
| JP2013518882A (ja) | 2013-05-23 |
| CN102822177A (zh) | 2012-12-12 |
| MX2012009074A (es) | 2012-08-23 |
| EP2531508A1 (en) | 2012-12-12 |
| AU2011213198A1 (en) | 2012-08-09 |
| AU2011213198B2 (en) | 2014-04-24 |
| WO2011097087A1 (en) | 2011-08-11 |
| US20120309776A1 (en) | 2012-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012019511A2 (pt) | compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. | |
| CO6531451A2 (es) | Compuesto de pirrolo[2,3-d]pirimidina | |
| CY2022003I1 (el) | Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak) | |
| ECSP11010904A (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| GEP201706620B (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| DK3808749T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme | |
| UY33454A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| MX2013005445A (es) | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). | |
| UA107951C2 (xx) | Похідні імідазопіридину як інгібітори jak | |
| GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
| BR112014004310A2 (pt) | composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| PL2658844T3 (pl) | Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb) | |
| HK1225712A1 (zh) | 作爲溶血磷脂酸受体拮抗剂的酰胺衍生物 | |
| CU20100261A7 (es) | Compuestos orgánicos | |
| NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa | |
| AU2011355362A8 (en) | 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: AH USA 42 LLC (US) |
|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B25D | Requested change of name of applicant approved |
Owner name: ZOETIS LLC (US) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |